What is Zacks Research’s Forecast for Exelixis Q3 Earnings?

Exelixis, Inc. (NASDAQ:EXEL) – Analysts at Zacks Research increased their Q3 2026 earnings per share (EPS) estimates for Exelixis in a report released on Friday, March 6th. Zacks Research analyst Team now forecasts that the biotechnology company will earn $0.74 per share for the quarter, up from their prior forecast of $0.71. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ FY2026 earnings at $2.96 EPS, Q1 2027 earnings at $0.82 EPS and FY2028 earnings at $4.23 EPS.

EXEL has been the subject of a number of other reports. Bank of America downgraded shares of Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price target for the company. in a research report on Monday, January 5th. Morgan Stanley upped their price target on Exelixis from $48.00 to $49.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Barclays raised their price objective on Exelixis from $41.00 to $44.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 4th. HC Wainwright boosted their target price on Exelixis from $52.00 to $54.00 and gave the stock a “buy” rating in a research report on Thursday, February 12th. Finally, UBS Group set a $41.00 target price on Exelixis in a report on Monday, January 5th. Ten equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $46.94.

Exelixis Trading Down 2.5%

EXEL stock opened at $41.29 on Monday. The company’s 50-day moving average price is $43.45 and its 200 day moving average price is $41.64. Exelixis has a 52 week low of $32.38 and a 52 week high of $49.62. The company has a market cap of $10.72 billion, a P/E ratio of 14.91, a P/E/G ratio of 0.95 and a beta of 0.41.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The business had revenue of $598.66 million for the quarter, compared to analysts’ expectations of $609.17 million. During the same period in the prior year, the company posted $0.55 EPS. The business’s revenue for the quarter was up 5.6% on a year-over-year basis.

Institutional Trading of Exelixis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Exelixis by 81.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock worth $1,592,000 after buying an additional 19,407 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Exelixis by 4.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock worth $54,153,000 after purchasing an additional 68,133 shares during the period. Focus Partners Wealth boosted its holdings in shares of Exelixis by 83.4% during the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after purchasing an additional 17,483 shares during the last quarter. Geneos Wealth Management Inc. boosted its holdings in shares of Exelixis by 134.3% during the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 944 shares during the last quarter. Finally, Sivia Capital Partners LLC grew its position in shares of Exelixis by 23.8% in the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock valued at $633,000 after purchasing an additional 2,764 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Transactions at Exelixis

In other news, Director Jack L. Wyszomierski sold 99,574 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total value of $4,382,251.74. Following the completion of the transaction, the director directly owned 279,942 shares of the company’s stock, valued at $12,320,247.42. The trade was a 26.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Dana Aftab sold 47,918 shares of the company’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $44.50, for a total value of $2,132,351.00. Following the completion of the sale, the executive vice president owned 616,106 shares in the company, valued at $27,416,717. This represents a 7.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 362,849 shares of company stock worth $15,917,463 in the last quarter. Insiders own 2.85% of the company’s stock.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.